Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma

BACKGROUND: The effect of the addition of fotemustine and/or interferon (IFN) to standard therapy with dacarbazine alone in patients with advanced malignant melanoma was investigated in a multicenter, randomized 2x2 factorial design trial. METHODS: A total of 260 patients were randomly assigned to o...

Descripción completa

Detalles Bibliográficos
Autores principales: Daponte, Antonio, Signoriello, Simona, Maiorino, Luigi, Massidda, Bruno, Simeone, Ester, Grimaldi, Antonio Maria, Caracò, Corrado, Palmieri, Giuseppe, Cossu, Antonio, Botti, Gerardo, Petrillo, Antonella, Lastoria, Secondo, Cavalcanti, Ernesta, Aprea, Pasquale, Mozzillo, Nicola, Gallo, Ciro, Comella, Giuseppe, Ascierto, Paolo Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3598549/
https://www.ncbi.nlm.nih.gov/pubmed/23402397
http://dx.doi.org/10.1186/1479-5876-11-38

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3598549/
https://www.ncbi.nlm.nih.gov/pubmed/23402397
http://dx.doi.org/10.1186/1479-5876-11-38

Ejemplares similares